Bortezomib|CAS |DC Chemicals

Cas No.:
Chemical Name:	Bortezomib
Synonyms:	Bortezomib;MG-341;PS-341;[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid;dpba;VELCADE;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Bortezomib for research;Bortezomib (PS-341);((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid;bortezomib（Velcade®, Bortecad®, PS-341,MG-341）;Bortizomib; Bortezmib;Bortezomib Base;MG-341 PS-341;PS341;Radiciol;MLM341;BortezoMib R;BortezoMib-D8;MG-341 PS-341;Ps 341;N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE;Bortezomib (Velcade);[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid;[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid;Peptide boronate;69G8BD63PP;Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl
SMILES:	O=C([C@]([H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(C1C([H])=NC([H])=C([H])N=1)=O)N([H])[C@]([H])(B(O[H])O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H]
Formula:	C₁₉H₂₅BN₄O₄
M.Wt:	384.24
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC29221	PTP1B-IN-9	PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity.
DC11125	TCH-165	TCH-165 is a specific small molecule modulator of proteasome assembly, regulates the dynamic equilibrium between the 20S and 26S proteasome complexes, favoring 20S-mediated protein degradation.
DC10304	RA190	RA190, a bis-benzylidine piperidon, inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor RPN13.
DC4243	ONX-0914	ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.
DC5086	Ixazomib(MLN2238)	MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.
DC80430	Chlorohexane-PEG-clozapine	Chlorohexane-PEG-clozapine is a HaloTag PROTAC degrader based on Clozapine. Chlorohexane-PEG-clozapine leads to a significant decrease in the luminescence intensity and protein level of Halo-Eluc. (Pink: Ligands for Target Protein for PROTAC Target protein ligand; Blue: Ligands for E3 Ligase ligand ; Black: linker).
DC80157	Adenosine receptor antagonist 7	Adenosine receptor antagonist 7 is an orally active triple A1/A2A/A2B adenosine receptor antagonist with Ki values of 1.5, 0.6 and 21 nM. Adenosine receptor antagonist 7 shows potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells. Adenosine receptor antagonist 7 can enhance infiltration of effector T cells and increase the CD8+/Treg ratio companied with Avelumab. Adenosine receptor antagonist 7can be used for the research of cancer, such as colon cancer.
DC80120	7-APDB hydrochloride	7-APDB hydrochloride is a benzofuran compound and can be used for the research of neurological disease.
DC79698	Bortezomib	Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
DC79015	LXE408 fumarate	LXE408 fumarate is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 fumarate has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 fumarate has a low propensity to cross the blood brain barrier. LXE408 fumarate has the potential for visceral leishmaniasis (VL) research.